ZimVie Acquired by ARCHIMED in a $730 Million Agreement
ZimVie to be Acquired by ARCHIMED for $730 Million
ZimVie, a global leader in dental implants, has announced a definitive agreement to be acquired by an affiliate of ARCHIMED. This acquisition, valued at approximately $730 million, marks a new chapter for the company.
The deal, expected to close by the end of 2025, is subject to shareholder and regulatory approvals. UBS Investment Bank is serving as the exclusive financial advisor to ARCHIMED, while Centerview Partners is serving as the exclusive financial advisor to ZimVie. Latham & Watkins LLP is serving as the legal advisor to ARCHIMED, and Cravath, Swaine & Moore LLP is serving as the legal advisor to ZimVie.
Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie, expressed excitement about the new chapter for the company. He stated, "We are thrilled to partner with ARCHIMED and are confident that this partnership will provide strategic and financial backing for the expansion of our innovative dental technology."
ARCHIMED recognizes ZimVie's strong fundamentals and compelling growth potential. André-Michel Ballester, Managing Partner at ARCHIMED, expressed his excitement about partnering with ZimVie and its team. He said, "We are looking forward to supporting ZimVie in its next chapter and are committed to helping the company reach more patients globally."
In a move to expand its presence in the Chinese dental implant market, ZimVie has entered into a strategic distribution agreement with Osstem Implant, the largest dental implant manufacturer in Asia-Pacific. Under this agreement, Osstem will have exclusive commercial responsibility for ZimVie's implant systems in China.
ZimVie shareholders will receive $19 in cash per share, representing a 99% premium over ZimVie's 90-day volume-weighted average price of $9.57. The transaction is private, and as a result, ZimVie will be delisted from NASDAQ.
ZimVie's Board of Directors has approved the deal unanimously. The partnership with ARCHIMED aims to provide strategic and financial backing for the expansion of ZimVie's innovative dental technology. ARCHIMED looks forward to supporting ZimVie in its mission to improve smiles, function, and confidence through trusted dental implants, biomaterials, and digital workflow solutions.
In summary, ZimVie's acquisition by ARCHIMED is expected to create value for ZimVie's shareholders and provide strategic and financial backing for the expansion of its innovative dental technology. The company, headquartered in Palm Beach Gardens, Florida, with global facilities, is committed to advancing clinical science and technology fundamental to restoring daily life. With the partnership with ARCHIMED, ZimVie is poised to reach more patients globally.
- The acquisition of ZimVie, a global leader in dental implants, by ARCHIMED, is expected to bolster the financial standing of both businesses.
- The strategic partnership between ZimVie and ARCHIMED aims to inject capital into ZimVie, accelerating the expansion of its cutting-edge dental technology worldwide.
